In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain
Abstract
A single high dose of methylenedioxymethamphetamine, a psychedelic agent, produced a rapid and persistent depletion of striatal indoles similar to that observed following administration of the serotonergic neurotoxin p-chloroamphetamine. The drug had little effect on dopaminergic variables. Like p-choloroamphetamine, methylenedioxymethamphetamine was found to be a relatively selective agent for inducing [3H]serotonin release in vitro. The serotonin uptake inhibitor, citalopram, blocked both [3H]serotonin release in vitro and striatal serotonin depletion in vivo, indicating that both processes were carrier dependent. In vivo comparisons of the stereoisomers of methylenedioxymethamphetamine indicated two phases of serotonin depletion similar to those reported for p-chloroamphetamine. Although both the (+)- and (−)-stereoisomers produced an acute (3 hr) decrease in striatal indoles, the long-term effects of the drug showed stereoselectivity in that the (+)-enantiomer produced the most dramatic serotonin depletion. Comparison of the effects of the stereoisomers of methylenedioxymethamphetamine and its n-desmethyl analog, methylenedioxyamphetamine, on [3H]serotonin and [3H]dopamine release in vitro showed the (+)-enantiomer of both drugs to be the more potent releasing agent. In spite of its reported lack of hallucinogenic activity, (+)methylenedioxyamphetamine was found to be of a potency similar to that of (+)methylenedioxymethamphetamine in inducing [3H]serotonin release in vitro. The results are discussed in terms of the neurochemical similarities between methylenedioxy-methamphetamine and p-chloroamphetamine as well as the proposed role of serotonin release in the behavioral effects of methylenedioxymethamphetamine.
References (49)
- C.J. Schmidt et al.
Eur. J. Pharmac.
(1986) - A. Sherman et al.
Neuropharmacology
(1975) - C.J. Schmidt et al.
Eur. J. Pharmac.
(1985) - G.C. Wagner et al.
Brain Res.
(1980) - U. Braun et al.
J. pharm. Sci.
(1980) - N.Y. Liang et al.
Biochem. Pharmac.
(1982) - R.W. Fuller et al.
Eur. J. Pharmac.
(1975) - R.A. Glennon et al.
Eur. J. Pharmac.
(1983) - J. Heym et al.
Eur. J. Pharmac.
(1984) - R.A. Glennon et al.
Life Sci.
(1984)
Eur. J. Pharmac.
Neuropharmacology
Biochem. Pharmac.
Brain Res.
Life Sci.
Pharmac. Biochem. Behav.
Eur. J. Pharmac.
J. Pharmac. exp. Ther.
J. Pharmac, exp. Ther.
Cited by (262)
The role of extracellular serotonin and MDMA in the sensitizing effects of MDMA
2022, Behavioural Brain ResearchMDMA is a non-selective monoamine releasing stimulant with potent serotonergic effects - a pharmacological effect not typically associated with drugs of misuse or efficacious reinforcers. Nonetheless, MDMA is misused by humans and self-administered by laboratory animals. We have previously shown that repeated exposure to MDMA sensitized both the locomotor activating and reinforcing effects of MDMA in rats. Because repeated MDMA exposure often results in decreased markers of serotonin neurotransmission, it is possible that this might underlie the sensitizing effects of MDMA. This was examined in the current study. Male Sprague-Dawley rats were stereotaxically implanted with guide cannula in the medial striatum. They were then pre-treated with saline (n = 11) or MDMA (10 mg/kg, i.p.; n = 10), once daily for five days. Two-days later, all rats received ascending doses of MDMA (0.0, 5.0, 10.0, mg/kg, i.p.) administered at 2 hr intervals, during which locomotor activity was measured and microdialysis samples were collected. Microdialysates were analyzed using liquid chromatography-mass spectrometry and the concentrations of serotonin and MDMA were quantified. Acute MDMA administration produced dose-dependent increases in locomotor activity, which was significantly enhanced by MDMA pre-treatment. Acute MDMA also produced dose-dependent increases in medial-striatal serotonin and MDMA, but this was not impacted by MDMA pre-treatment. These results suggest that the sensitizing effects of MDMA are not due to changes in MDMA-produced synaptic overflow of serotonin in the medial striatum or the absorption/elimination of systemically administered MDMA. More likely candidates are alterations in serotonin receptor mechanisms and/or dopamine neurotransmission following repeated exposure.
Neurotoxicity of N-Nitrosodimethylamine (NDMA) in Swiss albino mice and neuroprotection by nanocurcumin
2022, Materials Today: ProceedingsNitrosamine is a highly toxic compound which is released in various industries like rubber, cosmetics, pesticides etc. NDMA is formed in the processed food where sodium nitrite is used as preservative. It can also be found in alcoholic beverages and vegetables. Human’s exposure to NDMA is unavoidable. Mutagenic and hepatotoxic effects of NDMA has been reported but neurotoxicity data is not well established. In this study-four groups of Swiss albino mice were taken; Group I received the vehicle i.e. distilled water, group II received NDMA at the dose of 0.58 mg/kg body weight (1/25th of LD50) and group III received NDMA (0.58 mg/kg b.w.) + Nanocurcumin (20 mg/kg body weight) and group IV received only Nanocurcumin (20 mg/kg body weight). Various parameters of neuromuscular strength and neurotransmitters like Serotonin, Dopamine and Acetylcholinesterase were significantly decreased by NDMA treatment. Nanocurcumin administration along with NDMA didn’t cause any toxicity. In NDMA treated group’s antioxidant enzymes viz. SOD, catalase and glutathione peroxidase were significantly reduced whereas nanocurcumin showed protective effects as the nanocurcumin administration with NDMA showed near normal levels of the antioxidant enzymes. Cerebral cortex showed pia mater encephalic, intracellular and extracellular vacuoles, irregular, pyramidal cells and broadening vessel peripheral clearance was also seen in NDMA treatment group, which were normal in the control and nanocurcumin treated group. These findings proved that NDMA caused neurotoxicity at the tested dose level and nanocurcumin have neuroprotective potential against NDMA treatment.
3,4-Methylenedioxymethamphetamine (MDMA) Alters Synaptic Dopamine Release in the Dorsal Striatum Through Nicotinic Receptors and DAT Inhibition
2018, NeuroscienceAn increase of extracellular dopamine (DA) has been implicated in the psychostimulant properties of 3,4-methylenedioxymethamphetamine (MDMA). Although this drug has been reported to affect the DA uptake transporter (DAT), it might activate other mechanisms to regulate the outflow of DA in the brain. Our aim was to examine the overall effects of MDMA on the release of DA in the striatum.
We studied the effect of MDMA on stimulus-evoked synaptic DA release in dorsal striatal slices of mice using in vitro amperometric techniques. We also tested the effects of MDMA on the nicotine-induced responses in substantia nigra pars compacta (SNpc) neurons using intracellular electrophysiological recordings.
MDMA (1–30 µM) depressed the amplitude and prolonged the decay-time of synaptic DA release in the striatum. Interestingly, in the presence of the broad nicotinic receptor antagonist mecamylamine, and the more selective α4β2 antagonist dihydroβerythroidine (DHβE), MDMA enhanced both peak and duration of DA release. A similar effect was found on cocaine-insensitive (DAT-CI) mice slices.
Concentrations of MDMA higher than 100 µM enhanced striatal DA outflow that was in turn, reduced by cocaine.
Electrophysiological recordings of dopaminergic neurons in SNpc showed that MDMA depressed the effects of nicotine.
Our data are consistent with a prevalent MDMA-induced inhibition of the synaptic release of DA in the dorsal striatum mediated by an interaction with nicotinic receptors. This drug also blocks DAT acting on a different site from cocaine and, at higher concentrations, has amphetamine-like releasing properties.
The Developing Nervous System
2018, Comprehensive Toxicology: Third EditionBecause of the complexity and temporal features of the manifestations of the developing nervous system and/or developmental neurotoxicity, these areas of study may benefit greatly by monitoring alterations in gene and protein expression and cell signaling processes, and by using pharmacokinetic, behavioral, and imaging biomarkers. The developing nervous system possesses certain characteristics that may alter its susceptibility to toxicants as compared to the adult nervous system. Therefore, in the developing nervous system, where diverse cell types are differentiating from various primordial cells, the opportunity for differential toxicant effects is enhanced compared to mature, generally non-dividing cells of the adult nervous system.
Separating the agony from ecstasy: R(–)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice
2018, NeuropharmacologyS,R(+/–)-3,4-methylenedioxymethamphetamine (SR-MDMA) is an amphetamine derivative with prosocial and putative therapeutic effects. Ongoing clinical trials are investigating it as a treatment for post-traumatic stress disorder (PTSD) and other conditions. However, its potential for adverse effects such as hyperthermia and neurotoxicity may limit its clinical viability. We investigated the hypothesis that one of the two enantiomers of SR-MDMA, R-MDMA, would retain the prosocial and therapeutic effects but with fewer adverse effects. Using male Swiss Webster and C57BL/6 mice, the prosocial effects of R-MDMA were measured using a social interaction test, and the therapeutic-like effects were assessed using a Pavlovian fear conditioning and extinction paradigm relevant to PTSD. Locomotor activity and body temperature were tracked after administration, and neurotoxicity was evaluated post-mortem. R-MDMA significantly increased murine social interaction and facilitated extinction of conditioned freezing. Yet, unlike racemic MDMA, it did not increase locomotor activity, produce signs of neurotoxicity, or increase body temperature. A key pharmacological difference between R-MDMA and racemic MDMA is that R-MDMA has much lower potency as a dopamine releaser. Pretreatment with a selective dopamine D1 receptor antagonist prevented SR-MDMA-induced hyperthermia, suggesting that differential dopamine signaling may explain some of the observed differences between the treatments. Together, these results indicate that the prosocial and therapeutic effects of SR-MDMA may be separable from the stimulant, thermogenic, and potential neurotoxic effects. To what extent these findings translate to humans will require further investigation, but these data suggest that R-MDMA could be a more viable therapeutic option for the treatment of PTSD and other disorders for which SR-MDMA is currently being investigated.
Sex differences in the strategies of spatial learning in prenatally-exposed rats treated with various drugs in adulthood
2017, Behavioural Brain ResearchIn the present study we investigated the sex differences in the effect of adult long-term drug treatment on cognitive functions of Wistar rats, which were prenatally exposed to MA (5 mg/kg) or saline. Cognitive functions were tested as an ability of spatial learning in the Morris Water Maze (MWM), which consisted of three types of tests: “Place Navigation Test”; “Probe Test”, and “Memory Recall Test”. Adult animals were injected daily, after completion of the last trial, either with saline or cocaine (COC; 5 mg/kg), MDMA (3,4-methylenedioxy-methamphetamine; 5 mg/kg), morphine (MOR; 5 mg/kg), or delta-9-tetrahydrocannabinol (THC; 2 mg/kg). Results revealed worsened MWM performance in female rats after drug treatment in adulthood. Not only were traditionally investigated parameters affected by drug treatment (latency of platform acquisition, search strategy, distance traveled), but also strategies used by animals (thigmotaxis, scanning). Analyses of search strategies observed in the Place Navigation Test, as well as in the Memory Recall Test, demonstrated variations in the percentage of time spent in thigmotaxis and scanning in females after treatment with COC, MDMA, MOR, and THC. Although we did not see a sensitizing effect of prenatal MA, in some cases the effect of drug treatment in adulthood differed depending on the prenatal drug exposure. The data presented in this study demonstrates that exposure to drugs with various mechanisms of action alters spatial abilities of female rats in the MWM. Alterations in the effect of adult drug treatment with reference to prenatal drug exposure were also found in the present study.